Previous close | 0.1670 |
Open | 0.1595 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.1670 - 0.1670 |
52-week range | 0.0900 - 0.2200 |
Volume | |
Avg. volume | 82,295 |
Market cap | 29.168M |
Beta (5Y monthly) | 2.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”). On May 27, 2024, the C
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, was granted protection pursuant to an initial order (as amended, the “Initial Order”) issued under the Companies' Creditors Arrangement Act (“CCAA”) by the Québec Superior Court (Commercial Division) (the “Court”). The Initial Or
MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announced today that the Québec Superior Court (Commercial Division) (the “Court”) has issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”).